Last reviewed · How we verify
Bactrim DS
At a glance
| Generic name | Bactrim DS |
|---|---|
| Also known as | sulfamethoxazle-trimethroprim DS |
| Sponsor | R. Stephen Rankin, M.D. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effects of Treatments on Atopic Dermatitis (PHASE2)
- Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients (PHASE4)
- Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis (PHASE4)
- STaph Aureus Resistance-Treat Early and Repeat (STAR-TER) (PHASE2)
- Role of Prophylactic Postoperative Antibiotics in HoLEP (PHASE4)
- Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (PHASE3)
- [18F]Fluoropropyl-Trimethoprim ([18F]F-TMP) PET/CT Imaging to Evaluate Biodistribution and Kinetics in Human Subjects (PHASE1)
- Collaborative Urological Prosthetics Investigation Directive Research Group (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bactrim DS CI brief — competitive landscape report
- Bactrim DS updates RSS · CI watch RSS
- R. Stephen Rankin, M.D. portfolio CI